Quarterly
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
revenue | ||||||||||||
research and development collaborations | 48,726,000 | 27,110,000 | 31,031,000 | 16,000,000 | 19,243,000 | 10,030,000 | 16,926,000 | 16,506,000 | 7,002,000 | 35,578,000 | 402,493,000 | 2,631,000 |
operating expenses: | ||||||||||||
research and development | 34,449,000 | 35,738,000 | 37,063,000 | 36,353,000 | 29,163,000 | 32,042,000 | 25,524,000 | 32,775,000 | 39,408,000 | 45,912,000 | 52,967,000 | 37,097,000 |
general and administrative | 14,951,000 | 16,985,000 | 16,185,000 | 13,852,000 | 15,679,000 | 15,790,000 | 14,823,000 | 16,968,000 | 21,708,000 | 16,947,000 | 30,131,000 | 15,892,000 |
impairment on acquired ipr&d | ||||||||||||
total operating expenses | 49,400,000 | 52,723,000 | 53,248,000 | 50,205,000 | 62,129,000 | 47,832,000 | 40,347,000 | 49,743,000 | 61,116,000 | 62,859,000 | 83,098,000 | 52,989,000 |
income from operations | -674,000 | -25,613,000 | -22,217,000 | -34,205,000 | -42,886,000 | -37,802,000 | -23,421,000 | -33,237,000 | -54,114,000 | -27,281,000 | 319,395,000 | -50,358,000 |
yoy | -98.43% | -32.24% | -5.14% | 2.91% | -20.75% | 38.57% | -107.33% | -34.00% | ||||
qoq | -97.37% | 15.29% | -35.05% | -20.24% | 13.45% | 61.40% | -29.53% | -38.58% | 98.36% | -108.54% | -734.25% | |
operating margin % | ||||||||||||
other income: | ||||||||||||
interest income | 3,426,000 | 3,424,000 | 4,082,000 | 4,785,000 | 5,154,000 | 5,920,000 | 5,049,000 | 5,026,000 | 4,825,000 | 4,805,000 | 1,733,000 | 1,125,000 |
other income | -621,000 | 49,000 | 344,000 | -204,000 | 114,000 | 304,000 | -832,000 | 634,000 | -209,000 | -487,000 | -692,000 | 1,358,000 |
total other income | 2,805,000 | 3,473,000 | 4,426,000 | 4,581,000 | 5,268,000 | 6,224,000 | 4,217,000 | 5,660,000 | 4,616,000 | 4,318,000 | 1,041,000 | 2,483,000 |
income before income taxes | 2,131,000 | -22,140,000 | -17,791,000 | -29,624,000 | -37,618,000 | -31,578,000 | -19,204,000 | -27,577,000 | -49,498,000 | -22,963,000 | 320,436,000 | -47,875,000 |
income tax recovery | 186,000 | -11,005,000 | 29,000 | |||||||||
net income | 2,317,000 | -22,636,000 | -23,506,000 | -29,850,000 | -37,686,000 | -31,653,000 | -14,482,000 | -28,687,000 | -51,152,000 | -24,353,000 | ||
yoy | -106.15% | -28.49% | 62.31% | 4.05% | -26.33% | 29.98% | ||||||
qoq | -110.24% | -3.70% | -21.25% | -20.79% | 19.06% | 118.57% | -49.52% | -43.92% | 110.04% | |||
net income margin % | ||||||||||||
other comprehensive income: | ||||||||||||
unrealized income on available for sale securities, net of tax of nil | 66,000 | 546,000 | -953,000 | 1,905,000 | -1,121,000 | |||||||
total other comprehensive income | 66,000 | 546,000 | -953,000 | 1,905,000 | -1,121,000 | 720,000 | ||||||
comprehensive income | 2,383,000 | |||||||||||
net earnings per common share | ||||||||||||
basic | 30 | |||||||||||
diluted | 30 | |||||||||||
weighted-average common stock outstanding | ||||||||||||
basic | 75,337,168,000 | 75,171,020,000 | 75,846,681,000 | 76,128,531,000 | 76,392,593,000 | 76,214,833,000 | 68,863,010,000 | 70,575,773,000 | 67,281,028,000 | 66,739,308,000 | 65,194,775,000 | 66,477,016,000 |
diluted | 77,378,449,000 | 75,226,387,000 | 75,878,738,000 | 76,157,101,000 | 76,396,217,000 | 76,248,158,000 | 68,863,010,000 | 70,575,773,000 | 67,284,511,000 | 66,742,080,000 | 65,249,184,000 | 66,478,157,000 |
income tax expense | -496,000 | -92,250 | -226,000 | -68,000 | -75,000 | |||||||
comprehensive loss | -22,090,000 | -24,646,250 | -27,945,000 | -37,866,000 | -32,774,000 | -26,457,750 | -29,172,000 | -53,026,000 | -23,633,000 | |||
net income per common share | ||||||||||||
basic | -300 | -320 | -390 | -490 | -420 | -190 | -410 | -760 | -360 | 4,770 | -720 | |
diluted | -300 | -320 | -390 | -490 | -420 | -190 | -410 | -760 | -370 | 4,760 | -720 | |
impairment on acquired in-process research and development assets | 4,321,750 | 17,287,000 | ||||||||||
other comprehensive loss: | ||||||||||||
unrealized loss on available for sale securities, net of tax of nil | -180,000 | -409,750 | -485,000 | -1,874,000 | ||||||||
total other comprehensive loss | -180,000 | -409,750 | -485,000 | -1,874,000 | ||||||||
income tax (expense) recovery | -1,038,500 | -1,110,000 | -1,654,000 | -1,390,000 | ||||||||
unrealized gain on available for sale securities, net of tax of nil | 720,000 | |||||||||||
net income and comprehensive loss | -46,272,500 | -47,846,000 | ||||||||||
weighted-average common shares outstanding | ||||||||||||
basic | 75,337,168,000 | 75,171,020,000 | 75,846,681,000 | 76,128,531,000 | 76,392,593,000 | 76,214,833,000 | 68,863,010,000 | 70,575,773,000 | 67,281,028,000 | 66,739,308,000 | 65,194,775,000 | 66,477,016,000 |
diluted | 77,378,449,000 | 75,226,387,000 | 75,878,738,000 | 76,157,101,000 | 76,396,217,000 | 76,248,158,000 | 68,863,010,000 | 70,575,773,000 | 67,284,511,000 | 66,742,080,000 | 65,249,184,000 | 66,478,157,000 |
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.